Literature DB >> 21030679

Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.

Stephen Hare1, Ann M Vos, Reginald F Clayton, Jan W Thuring, Maxwell D Cummings, Peter Cherepanov.   

Abstract

The development of HIV integrase (IN) strand transfer inhibitors (INSTIs) and our understanding of viral resistance to these molecules have been hampered by a paucity of available structural data. We recently reported cocrystal structures of the prototype foamy virus (PFV) intasome with raltegravir and elvitegravir, establishing the general INSTI binding mode. We now present an expanded set of cocrystal structures containing PFV intasomes complexed with first- and second-generation INSTIs at resolutions of up to 2.5 Å. Importantly, the improved resolution allowed us to refine the complete coordination spheres of the catalytic metal cations within the INSTI-bound intasome active site. We show that like the Q148H/G140S and N155H HIV-1 IN variants, the analogous S217H and N224H PFV INs display reduced sensitivity to raltegravir in vitro. Crystal structures of the mutant PFV intasomes in INSTI-free and -bound forms revealed that the amino acid substitutions necessitate considerable conformational rearrangements within the IN active site to accommodate an INSTI, thus explaining their adverse effects on raltegravir antiviral activity. Furthermore, our structures predict physical proximity and an interaction between HIV-1 IN mutant residues His148 and Ser/Ala140, rationalizing the coevolution of Q148H and G140S/A mutations in drug-resistant viral strains.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21030679      PMCID: PMC2993412          DOI: 10.1073/pnas.1010246107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex.

Authors:  C M Farnet; W A Haseltine
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

2.  Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis.

Authors:  Marcin Nowotny; Sergei A Gaidamakov; Robert J Crouch; Wei Yang
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

3.  Retroviral DNA integration: reaction pathway and critical intermediates.

Authors:  Min Li; Michiyo Mizuuchi; Terrence R Burke; Robert Craigie
Journal:  EMBO J       Date:  2006-02-16       Impact factor: 11.598

4.  Detecting folding motifs and similarities in protein structures.

Authors:  G J Kleywegt; T A Jones
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

5.  Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.

Authors:  Krishan K Pandey; Sibes Bera; Ajaykumar C Vora; Duane P Grandgenett
Journal:  Biochemistry       Date:  2010-09-28       Impact factor: 3.162

6.  Nucleoprotein intermediates in HIV-1 DNA integration visualized by atomic force microscopy.

Authors:  Svetlana Kotova; Min Li; Emilios K Dimitriadis; Robert Craigie
Journal:  J Mol Biol       Date:  2010-04-21       Impact factor: 5.469

Review 7.  Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.

Authors:  Damian J McColl; Xiaowu Chen
Journal:  Antiviral Res       Date:  2009-11-17       Impact factor: 5.970

8.  Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.

Authors:  Anneleen Hombrouck; Arnout Voet; Barbara Van Remoortel; Christel Desadeleer; Marc De Maeyer; Zeger Debyser; Myriam Witvrouw
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

9.  Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.

Authors:  Olivia Goethals; Reginald Clayton; Marcia Van Ginderen; Inge Vereycken; Elisabeth Wagemans; Peggy Geluykens; Koen Dockx; Rudy Strijbos; Veerle Smits; Ann Vos; Geert Meersseman; Dirk Jochmans; Kurt Vermeire; Dominique Schols; Sabine Hallenberger; Kurt Hertogs
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

Review 10.  HIV-1 IN inhibitors: 2010 update and perspectives.

Authors:  Christophe Marchand; Kasthuraiah Maddali; Mathieu Métifiot; Yves Pommier
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

View more
  121 in total

1.  HIV-1 Integrase Inhibitor-Inspired Antibacterials Targeting Isoprenoid Biosynthesis.

Authors:  Yonghui Zhang; Kai Li; Wei Zhu; Yi-Liang Liu; Rong Cao; Ran Pang; Eunhae Lee; Jordan Axelson; Mary Hensler; Ke Wang; Katie J Molohon; Yang Wang; Douglas A Mitchell; Victor Nizet; Eric Oldfield
Journal:  ACS Med Chem Lett       Date:  2012-04-03       Impact factor: 4.345

2.  Differential sensitivities of retroviruses to integrase strand transfer inhibitors.

Authors:  Yasuhiro Koh; Kenneth A Matreyek; Alan Engelman
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Probing chelation motifs in HIV integrase inhibitors.

Authors:  Arpita Agrawal; Jamie DeSoto; Jessica L Fullagar; Kasthuraiah Maddali; Shahrzad Rostami; Douglas D Richman; Yves Pommier; Seth M Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-27       Impact factor: 11.205

4.  Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.

Authors:  Xue Zhi Zhao; Kasthuraiah Maddali; Mathieu Metifiot; Steven J Smith; B Christie Vu; Christophe Marchand; Stephen H Hughes; Yves Pommier; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2011-03-21       Impact factor: 2.823

5.  HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants.

Authors:  Steven J Smith; Xue Zhi Zhao; Dario Oliveira Passos; Dmitry Lyumkis; Terrence R Burke; Stephen H Hughes
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

6.  MK-0536 inhibits HIV-1 integrases resistant to raltegravir.

Authors:  Mathieu Métifiot; Barry Johnson; Steven Smith; Xue Zhi Zhao; Christophe Marchand; Terrence Burke; Stephen Hughes; Yves Pommier
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

7.  Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A.

Authors:  S Reigadas; B Masquelier; C Calmels; M Laguerre; E Lazaro; M Vandenhende; D Neau; H Fleury; M L Andréola
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

8.  Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.

Authors:  Atsuko Hachiya; Karen A Kirby; Yoko Ido; Urara Shigemi; Masakazu Matsuda; Reiko Okazaki; Junji Imamura; Stefan G Sarafianos; Yoshiyuki Yokomaku; Yasumasa Iwatani
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

9.  A Peptide Derived from Lens Epithelium-Derived Growth Factor Stimulates HIV-1 DNA Integration and Facilitates Intasome Structural Studies.

Authors:  Min Li; Xuemin Chen; Huaibin Wang; Kellie A Jurado; Alan N Engelman; Robert Craigie
Journal:  J Mol Biol       Date:  2020-02-13       Impact factor: 5.469

10.  Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Authors:  Michael E Abram; Rebecca M Hluhanich; Derrick D Goodman; Kristen N Andreatta; Nicolas A Margot; Linda Ye; Anita Niedziela-Majka; Tiffany L Barnes; Nikolai Novikov; Xiaowu Chen; Evguenia S Svarovskaia; Damian J McColl; Kirsten L White; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.